Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Frailty, disability and patient-reported outcomes in apixaban users — Stefano Fumagalli (2025) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Frailty, disability and patient-reported outcomes in apixaban users
Shared by
Giancarlo Agnelli
University of Perugia
Frailty, disability and patient-reported outcomes in apixaban users
Letter
2025
en
Authors
+2 more
SF
Stefano Fumagalli
GP
Giuseppe Di Pasquale
GM
Giulio Molon
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Letter
2024
Patient-reported outcomes and apixaban therapy in older patients
Stefano Fumagalli
,
Giuseppe Di Pasquale
,
Simone Pupo
,
Giancarlo Agnelli
,
Niccolò Marchionni
Letter
2025
Apixaban and the improved psychologic profile in frailty and disability. Myth or reality?
Stefano Fumagalli
,
Giuseppe Di Pasquale
,
Giulio Molon
,
Giancarlo Agnelli
,
Niccolò Marchionni
Article
2017
Reporting of Patient-Reported Outcomes in Randomized Trials
Melanie Calvert
,
Jane Blazeby
,
Douglas G. Altman
,
Dennis A. Revicki
,
David Moher
,
Michael Brundage
Article
2013
Reporting of Patient-Reported Outcomes in Randomized Trials
Melanie Calvert
,
Jane Blazeby
,
Douglas G. Altman
,
Dennis A. Revicki
,
David Moher
,
Michael Brundage
,
for the CONSORT Group
Article
2022
570 FRAILTY AND DISABILITY IN OLDER PATIENTS AND THE EFFECTS OF APIXABAN ON QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS. THE EXPERIENCE OF THE APULEIO STUDY
Simone Pupo
,
Giuseppe Di Pasquale
,
D. Poli
,
Giancarlo Agnelli
,
Niccolò Marchionni
,
Stefano Fumagalli
.jpg){kind=small}
Discussion(0)
No comments yet. Be the first to comment.